Head-to-head evidence
AZD8630 vs Tezepelumab (APFS)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: TSLP · full Asthma pipeline
AZD8630
Developed by AstraZeneca and partners
NCT06529419 · Phase 2 · completed
The study randomized 537 participants across three AZD8630 dose groups and placebo, with participants, care providers, investigators, and outcome assessors quadruple-blinded. Its primary endpoint was a clinical exacerbation-related measure, but the primary comparison cannot yet be judged because results have not been reported.
Tezepelumab (APFS)
Marketed by AstraZeneca
NCT03968978 · Phase 3 · completed
The study randomized 216 participants 1:1 to two active device types but was open-label, with no placebo or blinded control. Its primary endpoint was successful device administration rather than a clinical asthma outcome, and although arm-specific results were posted, the registry does not state whether the between-device comparison was statistically significant.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AZD8630's landscape · Tezepelumab (APFS)'s landscape